Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Affymax and Takeda Report Long-Term Safety and Effectiveness Data of Hematide in Chronic Renal Failure Patients With Anemia
April 27th, 2008
Affymax, Inc. (Nasdaq:AFFY) and Takeda Global Research & Development announced data from their ongoing Phase 2 trial to assess the long-term safety and tolerability of Hematide(TM), a potential treatment of anemia. These data showed that Hematide, dosed once every four weeks, successfully maintained mean hemoglobin levels between 11 and 12 g/dL for up to 18 months in hemodialysis patients who previously were treated with epoetin alfa. Hematide appeared generally well-tolerated. Robert Geronemus, M.D., associate professor, Florida Atlantic University and medical director, South Florida Research Institute, is the lead author of the poster which was presented at the...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-27)
|
